Physician profile
Phyllis C Fiveash
NPI 1689996282
$11,617.82
in general payments reported to CMS, 2019-2025
64 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,377 · 2022: $2,044 · 2023: $2,562 · 2024: $2,414 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,155 · Education: $42.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,154.58 |
| Education | $42.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $941.73 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $885.98 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $744.40 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Pfizer INC. | $630.20 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $618.20 | 2021-2025 | Kisqali |
| Janssen Biotech, INC. | $512.24 | 2021-2025 | Tecvayli, Darzalex, Imbruvica |
| Eisai INC. | $462.63 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $437.93 | 2021-2025 | Opdivo, Opdualag |
| Seagen INC. | $429.49 | 2021-2023 | Adcetris, Tivdak, Padcev |
| Gilead Sciences, INC. | $379.05 | 2022-2025 | Trodelvy |
| Amgen INC. | $373.78 | 2021-2022 | |
| Celgene Corporation | $354.50 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $353.69 | 2021-2025 | Ninlaro, Iclusig |
| Beigene USA, INC. | $316.58 | 2021-2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $313.97 | 2021-2025 | Injectafer, Enhertu |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Fiveash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.